By Counterforce Health Team in Xenpozyme (olipudase alfa-rpcp) —

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Blue Cross Blue Shield in Virginia: Complete Timeline & Appeal Guide

Quick Answer: Getting Xenpozyme Covered by Blue Cross Blue Shield in Virginia

Xenpozyme (olipudase alfa-rpcp) requires prior authorization from Blue Cross Blue Shield Virginia, typically decided within 72 hours for standard requests. To get approved: (1) Ensure you have documented ASMD diagnosis with genetic/enzyme confirmation, (2) Submit complete prior authorization through your provider using Anthem's ICR portal or designated fax, (3) If denied, file internal appeal within plan deadlines, then external review through Virginia's State Corporation Commission within 120 days. Start with Anthem's Prior Authorization Lookup Tool to verify current requirements.

Table of Contents

What Affects Xenpozyme Approval Timing

Several factors influence how quickly Blue Cross Blue Shield Virginia processes your Xenpozyme prior authorization:

Benefit Type Impact:

  • Commercial plans: Standard 72-hour review
  • Medicare Advantage: May follow Medicare Part B or Part D timelines
  • Medicaid managed care: Often 14-day standard review

Documentation Completeness: The most critical factor is having complete clinical documentation upfront. Anthem requires specific evidence including:

  • Laboratory-confirmed ASMD diagnosis (genetic/enzymatic testing)
  • Disease-related clinical manifestations documentation
  • Prior treatment history and current clinical status
  • Baseline liver function tests and spleen/lung metrics

Complexity of Medical History: Cases requiring additional clinical review or specialist consultation may extend beyond the standard 72-hour window.

Pre-Submission Preparation (0-2 Days)

Essential Documentation Checklist

Before submitting your prior authorization, gather these required documents:

Clinical Requirements:

  • ASMD diagnosis confirmation with acid sphingomyelinase (ASM) enzyme activity <10% of normal
  • SMPD1 gene mutation analysis results
  • Baseline assessments: liver function tests, complete blood count, lipid panel
  • Documentation of hepatosplenomegaly, pulmonary involvement, or other manifestations
  • Previous treatment attempts and outcomes (if applicable)

Insurance Information:

  • Current Blue Cross Blue Shield Virginia member ID
  • Policy effective dates and benefit verification
  • Confirmation of specialty pharmacy network requirements

Provider Documentation:

  • Prescriber DEA and NPI numbers
  • Clinic/infusion center details for site of care
  • Treatment plan including dosing schedule and monitoring
Tip: Use Anthem's Prior Authorization Lookup Tool to verify current requirements before gathering documents.

Submission to Initial Review (1-5 Days)

Step-by-Step Submission Process

1. Submit Through Preferred Channels (Day 1)

  • Primary: Interactive Care Reviewer (ICR) on Availity portal
  • Alternative: Designated fax for medical injectables
  • Required: Complete prior authorization form with all clinical attachments

2. Initial Eligibility Screening (Days 1-2) Anthem's utilization management team verifies:

  • Member eligibility and active coverage
  • Prior authorization requirement confirmation
  • Complete documentation submission

3. Clinical Review Process (Days 2-3) Medical reviewers assess:

  • FDA-approved indication alignment
  • Clinical necessity based on ASMD diagnosis
  • Appropriate dosing and administration plan
  • Safety considerations and monitoring requirements

4. Decision Communication (Day 3-5)

  • Approval: Authorization number and coverage duration provided
  • Denial: Specific reasons and appeal rights included
  • Pending: Additional information request with response deadline

Decision Window & Outcomes

Typical Review Timelines

Request Type Standard Timeline Expedited Timeline Notes
Initial Authorization 72 hours 24 hours Expedited if urgent medical need
Reauthorization 72 hours 24 hours Submit 30 days before expiration
Appeal Review 30 days 72 hours Internal plan review

Reading Your Approval Letter

Approved Requests Include:

  • Authorization number for pharmacy/provider reference
  • Coverage duration (typically 6 months initially)
  • Approved dosing and frequency
  • Specialty pharmacy network requirements
  • Reauthorization timeline and requirements

Partial Approvals May Specify:

  • Modified dosing or frequency
  • Additional monitoring requirements
  • Site of care restrictions
  • Quantity limitations

If Denied: Virginia Appeal Process

Virginia provides robust appeal rights through multiple levels of review.

Internal Plan Appeals

Level 1: Standard Internal Appeal

  • Deadline: File within plan-specified timeframe (typically 60 days)
  • Timeline: Decision within 30 days (72 hours if expedited)
  • How to File: Through member portal, phone, or written request

Level 2: Independent Medical Review Some plans offer a second internal review level before external review.

Virginia External Review Process

Eligibility Requirements:

  • Completed internal plan appeals process
  • Denial based on medical necessity or experimental/investigational determination
  • Virginia-issued plan or participating self-funded plan

Filing Process:

  1. Submit within 120 days of final internal denial
  2. Contact: Virginia State Corporation Commission Bureau of Insurance
  3. Phone: 1-877-310-6560 for guidance
  4. Form: Complete Form 216-A (External Review Request)

Review Timeline:

  • Standard: Decision within 45 days
  • Expedited: 72 hours for urgent cases
  • Cancer treatment: May proceed directly to external review

Independent Review Organization (IRO) Process:

  • Random assignment to avoid conflicts of interest
  • Board-certified physicians review all evidence
  • Final and binding decision on both patient and insurer
  • If overturned, insurer must authorize within 24 hours
From our advocates: We've seen patients successfully overturn Xenpozyme denials by providing comprehensive genetic testing documentation and specialist letters detailing why enzyme replacement therapy is medically necessary for their specific ASMD manifestations. The key is addressing every denial reason with specific clinical evidence.

Renewal Cycles & Reauthorization

Planning for Continued Coverage

Initial Authorization: Typically approved for 6 months Reauthorization Requirements:

  • Evidence of clinical benefit (reduced spleen size, improved pulmonary function)
  • Absence of unacceptable toxicity
  • Continued medical necessity documentation
  • Updated laboratory results

Timing Strategy: Start reauthorization 30-45 days before expiration to avoid treatment interruptions.

Documentation for Renewal:

  • Progress notes demonstrating clinical improvement
  • Updated imaging or laboratory results
  • Physician assessment of ongoing benefit
  • Patient tolerance and quality of life measures

Timeline Visual & Milestones

Expected Timeline Ranges

Milestone Best Case Typical Complex Case
Document gathering 1 day 2 days 5 days
Submission to review Same day 1 day 2 days
Initial decision 1 day 3 days 5 days
Specialty pharmacy processing 1 day 2 days 3 days
Total to first infusion 3 days 8 days 15 days

If Appeals Are Needed

Appeal Level Filing Deadline Decision Timeline Total Added Time
Internal Appeal 60 days 30 days (3 days expedited) 30-60 days
Virginia External Review 120 days from final denial 45 days (72 hours expedited) 45-90 days

Time-Saving Tips for Faster Approval

Portal Optimization

  • Use Availity ICR: Electronic submission is faster than fax
  • Complete profiles: Ensure all provider information is current
  • Track status: Monitor submission progress through portal

Documentation Strategies

  • Bundle evidence: Submit all required documents together initially
  • Specialist routing: Have rare disease specialists submit requests when possible
  • Template letters: Use Counterforce Health's platform to generate evidence-backed appeals that align with Blue Cross Blue Shield's specific criteria

Communication Best Practices

  • Peer-to-peer requests: Ask for medical director review for complex cases
  • Expedited flags: Clearly mark urgent requests with clinical justification
  • Follow-up timing: Call within 24 hours if no acknowledgment received

Common Denial Reasons & Solutions

Denial Reason Required Fix Documentation Needed
No documented ASMD diagnosis Provide genetic/enzymatic confirmation ASM enzyme activity <10%, SMPD1 mutation results
Insufficient clinical evidence Submit comprehensive clinical assessment Specialist evaluation, imaging, laboratory results
Site of care issues Verify approved administration locations Infusion center network verification
Quantity over limits Justify weight-based dosing Patient weight, BSA calculations, dosing rationale
Missing monitoring plan Provide safety oversight protocol Liver function monitoring, infusion reaction management

Solutions for Each Denial Type

Diagnostic Documentation Gaps: Contact the ordering physician to ensure both enzyme activity testing and genetic confirmation are included. ASMD diagnosis requires both biochemical and molecular evidence.

Clinical Necessity Questions: Provide detailed documentation of disease manifestations, including organomegaly measurements, pulmonary function tests, and quality of life impacts.

Administrative Issues: Verify current formulary status, network requirements, and submission procedures through the provider portal.

FAQ: Xenpozyme Coverage in Virginia

How long does Blue Cross Blue Shield prior authorization take in Virginia? Standard requests are decided within 72 hours. Expedited requests for urgent medical situations are processed within 24 hours.

What if Xenpozyme is non-formulary on my plan? You can request a formulary exception by demonstrating medical necessity and lack of effective formulary alternatives. The process follows the same timeline as prior authorization.

Can I request an expedited appeal in Virginia? Yes, if your doctor certifies that waiting could seriously jeopardize your health. Expedited internal appeals are decided within 72 hours, and expedited external reviews within 72 hours for urgent cases.

Does step therapy apply to Xenpozyme? Step therapy typically doesn't apply since there are no FDA-approved alternatives for ASMD. However, plans may require documentation of supportive care attempts.

What happens if I move from another state to Virginia? Your coverage continues under your existing Blue Cross Blue Shield plan, but appeal rights follow Virginia law if your plan is Virginia-issued.

How much does Xenpozyme cost without insurance? The wholesale acquisition cost ranges from $1,515.25 per 4mg vial to $7,576.23 per 20mg vial, making annual costs potentially exceed $400,000 depending on patient weight and dosing.

Are there patient assistance programs available? Sanofi offers patient support programs. Check the Xenpozyme website for current assistance options and eligibility requirements.

What if my employer plan is self-funded? Self-funded plans may opt into Virginia's external review process. If not, federal external review through HHS may be available. Contact the Virginia Bureau of Insurance for guidance.

When Coverage Gets Complicated

Sometimes insurance approval requires additional advocacy. Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to draft point-by-point rebuttals using the right medical evidence—from FDA labeling to peer-reviewed studies—that align with each payer's specific requirements.

For Xenpozyme cases, this means identifying whether denials stem from diagnostic documentation gaps, medical necessity questions, or administrative issues, then crafting appeals that address Blue Cross Blue Shield Virginia's exact criteria with appropriate clinical citations and procedural requirements.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage processes and should not be considered medical or legal advice. Coverage decisions depend on individual circumstances and specific plan terms. Always consult with your healthcare provider about treatment decisions and contact your insurance plan directly for coverage questions. For assistance with Virginia insurance issues, contact the State Corporation Commission Bureau of Insurance at 1-877-310-6560.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.